Updating results

457 results

Sort: Relevance | Date

Osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302]

In development [GID-TA10255] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer ID1546

In development [GID-TA10417] Expected publication date: 21 April 2021

Technology appraisal guidance In development

Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]

In development [GID-TA10529] Expected publication date: 24 June 2020

Technology appraisal guidance In development

Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer [ID1598]

In development [GID-TA10496] Expected publication date: 21 October 2020

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID1504

In development [GID-TA10400] Expected publication date: 26 February 2020

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating unresectable advanced oesophageal cancer when standard chemotherapy has failed [ID1249]

In development [GID-TA10222] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Selective internal radiation therapies for treating hepatocellular carcinoma ID1276

In development [GID-TA10381] Expected publication date: TBC

Technology appraisal guidance In development

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm ID1556

In development [GID-TA10482] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Entrectinib for treating ROS1-positive locally advanced or metastatic non-small-cell lung cancer [ID1541]

In development [GID-TA10415] Expected publication date: TBC

Technology appraisal guidance In development

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Highly specialised technologies guidance In development

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Highly specialised technologies guidance In development

Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (primary-progressive) - fingolimod [ID62]

In development [GID-TAG221] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - ximelagatran [ID376]

In development [GID-TAG377] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264

In development [GID-TA10365] Expected publication date: TBC

Technology appraisal guidance In development

Eltrombopag for untreated severe aplastic anaemia ID1198

In development [GID-TA10284] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

In development [GID-TA10338] Expected publication date: TBC

Technology appraisal guidance In development

Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413

In development [GID-TA10329] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

In development [GID-TA10322] Expected publication date: TBC

Technology appraisal guidance In development

Moxetumomab pasudotox for hairy-cell leukaemia [ID1142]

In development [GID-TA10288] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

In development [GID-TA10295] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

In development [GID-TA10394] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

In development [GID-TA10380] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331

In development [GID-TA10318] Expected publication date: TBC

Technology appraisal guidance In development

Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: TBC

Technology appraisal guidance In development

Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

In development [GID-TA10277] Expected publication date: TBC

Technology appraisal guidance In development

Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347

In development [GID-TA10264] Expected publication date: TBC

Technology appraisal guidance In development

Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

In development [GID-TA10236] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)

In development [GID-TA10233] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

In development [GID-TA10234] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]

In development [GID-TA10272] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

In development [GID-TA10271] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305

In development [GID-TA10244] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

In development [GID-TA10242] Expected publication date: TBC

Technology appraisal guidance In development

Recombinant human parathyroid hormone for treating hypoparathyroidism [1094]

In development [GID-TA10219] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Technology appraisal guidance In development

Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

In development [GID-TA10377] Expected publication date: TBC

Technology appraisal guidance In development

Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Technology appraisal guidance In development

Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

In development [GID-TA10353] Expected publication date: TBC

Technology appraisal guidance In development

Lenalidomide for untreated follicular lymphoma ID1245

In development [GID-TA10308] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (ID1375)

In development [GID-TA10360] Expected publication date: TBC

Technology appraisal guidance In development

Guadecitabine for untreated acute myeloid leukaemia ID1411

In development [GID-TA10325] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355

In development [GID-TA10321] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

In development [GID-TA10165] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]

In development [GID-TAG410] Expected publication date: TBC

Technology appraisal guidance In development